866-997-4948(US-Canada Toll Free)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Insights, Forecast to 2025

Published By :

QYResearch

Published Date : Nov 2018

Category :

Pharmaceutical

No. of Pages : 124 Pages

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
The classification of Chemotherapy Induced Peripheral Neuropathy Treatment includes Calcium channel 2-delta ligands, Antidepressants, Opioids and Other Drugs. And the proportion of Opioids in 2017 is about 27%, and the proportion is in decreasing trend from 2013 to 2017.
Chemotherapy Induced Peripheral Neuropathy Treatment is widely used for CIPN cause by Platinum Agents, Taxanes, Vinca Alkaloids and Others. The most proportion of Chemotherapy Induced Peripheral Neuropathy Treatment is used in Platinum Agents, and the proportion in 2017 is 42%.
North America is the largest sales place, with a sales market share nearly 41% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 27%.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is valued at 1300 million US$ in 2017 and will reach 2150 million US$ by the end of 2025, growing at a CAGR of 6.5% during 2018-2025. The objectives of this study are to define, segment, and project the size of the Chemotherapy Induced Peripheral Neuropathy Treatment market based on company, product type, end user and key regions.

This report studies the global market size of Chemotherapy Induced Peripheral Neuropathy Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions.
This research report categorizes the global Chemotherapy Induced Peripheral Neuropathy Treatment market by top players/brands, region, type and end user. This report also studies the global Chemotherapy Induced Peripheral Neuropathy Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Aptinyx
Asahi Kasei Pharma
Regenacy Pharmaceuticals
MAKScientific
Metys Pharmaceuticals
Nemus Bioscience
PledPharma
Sova Pharmaceuticals
DermaXon
Immune Pharmaceuticals
Kineta
Krenitsky Pharmaceuticals
PeriphaGen
Apexian Pharma
WinSanTor
Solasia Pharma

Market size by Product
Calcium Channel 2-delta Ligands
Antidepressants
Opioids
Others
Market size by End User
Platinum Agents
Taxanes
Vinca Alkaloids
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Chemotherapy Induced Peripheral Neuropathy Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2013 to 2017, and forecast to 2025.
To understand the structure of Chemotherapy Induced Peripheral Neuropathy Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chemotherapy Induced Peripheral Neuropathy Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Chemotherapy Induced Peripheral Neuropathy Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Chemotherapy Induced Peripheral Neuropathy Treatment are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy Induced Peripheral Neuropathy Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Product
1.4.2 Calcium Channel 2-delta Ligands
1.4.3 Antidepressants
1.4.4 Opioids
1.4.5 Others
1.5 Market by End User
1.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by End User
1.5.2 Platinum Agents
1.5.3 Taxanes
1.5.4 Vinca Alkaloids
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2013-2025
2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2013-2025
2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Growth Rate by Regions
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Regions
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers
3.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers
3.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers
3.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers
3.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2013-2018)
3.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2013-2018)
3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturers
3.4 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Product Types
3.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Product
4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by End User

6 North America
6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Product
6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment by End User

7 Europe
7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Product
7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by End User

8 Asia Pacific
8.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
8.1.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
8.1.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Product
8.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by End User

9 Central & South America
9.1 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
9.1.1 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
9.1.2 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by Product
9.3 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by End User

10 Middle East and Africa
10.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
10.1.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
10.1.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Product
10.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by End User

11 Company Profiles
11.1 Aptinyx
11.1.1 Aptinyx Company Details
11.1.2 Company Business Overview
11.1.3 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.1.4 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.1.5 Aptinyx Recent Development
11.2 Asahi Kasei Pharma
11.2.1 Asahi Kasei Pharma Company Details
11.2.2 Company Business Overview
11.2.3 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.2.4 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.2.5 Asahi Kasei Pharma Recent Development
11.3 Regenacy Pharmaceuticals
11.3.1 Regenacy Pharmaceuticals Company Details
11.3.2 Company Business Overview
11.3.Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.3.5 Regenacy Pharmaceuticals Recent Development
11.4 MAKScientific
11.4.1 MAKScientific Company Details
11.4.2 Company Business Overview
11.4.3 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.4.4 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.4.5 MAKScientific Recent Development
11.5 Metys Pharmaceuticals
11.5.1 Metys Pharmaceuticals Company Details
11.5.2 Company Business Overview
11.5.3 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.5.4 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.5.5 Metys Pharmaceuticals Recent Development
11.6 Nemus Bioscience
11.6.1 Nemus Bioscience Company Details
11.6.2 Company Business Overview
11.6.3 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.6.4 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.6.5 Nemus Bioscience Recent Development
11.7 PledPharma
11.7.1 PledPharma Company Details
11.7.2 Company Business Overview
11.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.7.5 PledPharma Recent Development
11.8 Sova Pharmaceuticals
11.8.1 Sova Pharmaceuticals Company Details
11.8.2 Company Business Overview
11.8.3 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.8.4 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.8.5 Sova Pharmaceuticals Recent Development
11.9 DermaXon
11.9.1 DermaXon Company Details
11.9.2 Company Business Overview
11.9.3 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.9.4 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.9.5 DermaXon Recent Development
11.10 Immune Pharmaceuticals
11.10.1 Immune Pharmaceuticals Company Details
11.10.2 Company Business Overview
11.10.3 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2013-2018)
11.10.4 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
11.10.5 Immune Pharmaceuticals Recent Development
11.11 Kineta
11.12 Krenitsky Pharmaceuticals
11.13 PeriphaGen
11.14 Apexian Pharma
11.15 WinSanTor
11.16 Solasia Pharma

12 Future Forecast
12.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Regions
12.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Regions 2018-2025
12.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Regions 2018-2025
12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Product
12.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Product 2018-2025
12.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Product 2018-2025
12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by End User
12.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
12.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
12.6 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
12.7 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
12.8 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Table

List of Tables and Figures

Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Table Chemotherapy Induced Peripheral Neuropathy Treatment Market Segments
Table Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Covered
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Product 2018-2025 (K Units) & (Million US$)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product 2013-2025
Figure Calcium Channel 2-delta Ligands Product Picture
Table Major Manufacturers of Calcium Channel 2-delta Ligands
Figure Antidepressants Product Picture
Table Major Manufacturers of Antidepressants
Figure Opioids Product Picture
Table Major Manufacturers of Opioids
Figure Others Product Picture
Table Major Manufacturers of Others
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by End User 2018-2025 (K Units)
Figure Platinum Agents
Figure Taxanes
Figure Vinca Alkaloids
Figure Others
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2013-2025 (Million US$)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2013-2025 (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions 2013-2018 (K Units) & (Million US$)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Regions 2013-2018 (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions 2013-2018
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions 2013-2018
Figure 2017 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Regions 2013-2018 (Million US$)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions 2013-2018
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions 2013-2018
Figure 2017 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2013-2018) (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers (2013-2018)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2017
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2013-2018) (Million USD)
Table Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2013-2018)
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Value Share by Manufacturers in 2017
Table Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Price (2013-2018) (USD/Unit)
Table Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table Date of International Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Product (2013-2018)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product in 2017
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Product (2013-2018) (Million US$)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Product (2013-2018)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Product (2013-2018)
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Product in 2017
Table Chemotherapy Induced Peripheral Neuropathy Treatment Price by Product 2013-2018 (USD/Unit)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by End User (2013-2018)
Figure Global Sales Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User (2013-2018)
Figure Global Sales Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User in 2017
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2013-2018 (K Units)
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2013-2018 (Million US$)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2013-2018) (K Units)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2013-2018)
Figure 2017 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2013-2018) (Million US$)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2013-2018)
Figure 2017 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (K Units)
Figure Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure 2017 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Product
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by End User (2013-2018)
Figure 2017 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2013-2018 (K Units)
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2013-2018 (Million US$)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2013-2018) (K Units)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2013-2018)
Figure 2017 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2013-2018) (Million US$)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2013-2018)
Figure 2017 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries
Figure Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure UK Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure UK Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure 2017 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Product
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by End User (2013-2018)
Figure 2017 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User
Figure Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2013-2018 (K Units)
Figure Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2013-2018 (Million US$)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2013-2018) (K Units)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2013-2018)
Figure 2017 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2013-2018) (Million US$)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2013-2018)
Figure 2017 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries
Figure China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Singapore Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Singapore Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure 2017 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Product
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by End User (2013-2018)
Figure 2017 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User
Figure Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2013-2018 (K Units)
Figure Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2013-2018 (Million US$)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2013-2018) (K Units)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2013-2018)
Figure 2017 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2013-2018) (Million US$)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2013-2018)
Figure 2017 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries
Figure Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure 2017 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Product
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by End User (2013-2018)
Figure 2017 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2013-2018 (K Units)
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2013-2018 (Million US$)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2013-2018) (K Units)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2013-2018)
Figure 2017 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries (2013-2018) (Million US$)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2013-2018)
Figure 2017 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries
Figure GCC Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure GCC Countries Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Figure South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2013-2018) (K Units)
Figure South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2013-2018) (Million US$)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product (2013-2018) (K Units)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Product (2013-2018)
Figure 2017 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Product
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by End User (2013-2018) (K Units)
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by End User (2013-2018)
Figure 2017 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by End User
Table Aptinyx Company Details
Table Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Aptinyx Recent Development

Table Asahi Kasei Pharma Company Details
Table Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Asahi Kasei Pharma Recent Development

Table Regenacy Pharmaceuticals Company Details
Table Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Regenacy Pharmaceuticals Recent Development

Table MAKScientific Company Details
Table MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table MAKScientific Recent Development

Table Metys Pharmaceuticals Company Details
Table Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Metys Pharmaceuticals Recent Development

Table Nemus Bioscience Company Details
Table Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Nemus Bioscience Recent Development

Table PledPharma Company Details
Table PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table PledPharma Recent Development

Table Sova Pharmaceuticals Company Details
Table Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Sova Pharmaceuticals Recent Development

Table DermaXon Company Details
Table DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table DermaXon Recent Development

Table Immune Pharmaceuticals Company Details
Table Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Table Immune Pharmaceuticals Recent Development

Table Kineta Company Details
Table Krenitsky Pharmaceuticals Company Details
Table PeriphaGen Company Details
Table Apexian Pharma Company Details
Table WinSanTor Company Details
Table Solasia Pharma Company Details
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Regions 2018-2025 (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Regions 2018-2025
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Regions 2018-2025 (Million US$)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Regions 2018-2025
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Product 2018-2025 (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Product 2018-2025
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Product 2018-2025 (Million US$)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Product 2018-2025
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by End User 2018-2025 (K Units)
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by End User 2018-2025
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Forecast (2018-2025) (K Units)
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate Forecast (2018-2025) (Million US$)
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Forecast (2018-2025) (K Units)
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate Forecast (2018-2025) (Million US$)
Figure Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Forecast (2018-2025) (K Units)
Figure Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate Forecast (2018-2025) (Million US$)
Figure Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Forecast (2018-2025) (K Units)
Figure Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate Forecast (2018-2025) (Million US$)
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Forecast (2018-2025) (K Units)
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate Forecast (2018-2025) (Million US$)
Table Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain
Table Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *